A first-in-human Phase I non-randomized open-label multicenter dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
